This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and VHH. These engineered antibodies are created to have heightened efficacy and overcome tumor resistance by binding to multiple targets simultaneously. Innovative engineering technologies are helping researchers achieve better PK/PD with an enhanced half-life and less immunogenicity. The demand for engineered antibodies is also driving Tier I pharmaceuticals to collaborate with key developers to expand their therapeutic expertise by adding multispecific antibodies to their portfolios. Developers, on their part, are partnering with AI/ML-based technology providers to enhance their antibody offerings.
The study identifies the different antibody formats and examines their applicability across disease areas. It looks at the key players developing innovative antibody discovery, engineering, and development services to facilitate the creation of engineered antibody formats. The study examines the factors driving and restraining the growth of engineered antibody therapeutics for cancer and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.
Key Questions This Study Answers
1. What are the key drivers and restraints in the development of engineered antibodies?
2. What are the applications of engineered antibodies across different disease areas? What are the key focus areas of R&D efforts?
3. Which disease areas are seeing increased adoption?
4. What are the key innovative discoveries and engineering technologies?
5. What does the funding landscape look like?
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Engineered Antibody Therapeutics for Cancer
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology
Scope of Analysis
Segmentation
Growth Drivers
Growth Restraints
Need for Engineered Antibodies
Challenges with Current Antibody Therapeutics
How Engineered Antibodies Therapeutics Help Overcome the Challenges with Traditional Antibodies
Engineered Antibody Formats—Multi-specificity for Better Efficacy
ADCs Explored for Oncology
Antibodies Fragments/Building Blocks
Analysis of Different Building Blocks for Different Antibody Formats
Analysis of Different Building Blocks for Different Antibody Formats (continued)
Key Innovators
Focus Area for Engineered Antibody Development
Antibody Engineering—Strategies to Develop Better Antibodies
Antibody Engineering—Strategies to Develop Better Antibodies (continued)
Types of BsAb Formats
Multispecifics Antibodies Formats/Engineering Technologies
Multispecifics Antibodies Formats/Engineering Technologies (continued)
Multispecific Antibody Applications Across Disease Areas
Emerging Innovations in Engineered Antibodies for Oncology
Immune Targeting Strategies of BsAbs
Immune Targeting Strategies of BsAbs (continued)
Therapeutic Utility of Fabs
Therapeutic Utility of Bivalent Antibody Fragments F(ab’)2
Therapeutic Utility of scFvs
Therapeutic Utility of Nanobodies/VHH
Therapeutic Utility of Trispecific Antibodies
Therapeutic Utility of Tetraspecific Antibodies
Increasing Interest From Tier I Pharma Companies in Oncology
Antibody Development Platforms—Humanized Mouse
Antibody Development Platforms—Transgenic Animal
Antibody Development Platforms—Transgenic Animal (continued)
Strategies to Achieve High Throughput Screening
Innovation Around Microfluidics and Droplet-based Technologies
Innovation Around Single Cell Analysis
Innovation Around Functional Screening
Use of AI/ML Across Different Aspects of Antibody Development
Use of AI/ML Across Different Aspects of Antibody Development (continued)
Recent Private Funding for the Development of Antibody Therapeutics
Recent Private Funding for the Development of Antibody Therapeutics (continued)
Growth Opportunity 1: Improved Optimization
Growth Opportunity 1: Improved Optimization
Growth Opportunity 2: Focus on Novel Antibody Formats
Growth Opportunity 2: Focus on Novel Antibody Formats
Growth Opportunity 3: Application Expansion
Growth Opportunity 3: Application Expansion
Technology Readiness Levels (TRL): Explanation
Benefits and Impacts of Growth Opportunities
Next Steps
Take the Next Step
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| Author | Priyanka Jain |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Engineered Antibody Therapeutics |
| Keyword 2 | Cancer Treatment |
| Keyword 3 | Biopharmaceuticals |
| Podcast | No |
| WIP Number | DAFA-01-00-00-00 |
Engineered Antibody Therapeutics for Cancer
Technology advances and increasing interest from Tier I pharmaceuticals are driving the growth of engineered antibodies
25-Jul-2024
Global
Technology Research